Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403621 · ClinicalTrials.gov registry record · Phase 1
Hypertrophic Scar Prevention by Novel Topical Gel Application
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03403621: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT03403621 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03403621, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Researchers are trying to find out more about the side effects of topical (applied to the skin) Pentamidine, to determine if it is safe for use in people. They also want to find out if topical use of Pentamidine can help treat hypertrophic scars. Pentamidine is a medicine that is currently used to treat certain kinds of infection. It is most often given by intravenous (into a vein) or inhalation (through a breathing device). This medication is approved by the U.S. Food and Drug Administration (FDA) for use in these forms. Everyone in this study will receive topical Pentamidine (TP) in a silicone based gel (PCCA Pracasil Plus). Topical treatment of Pentamidine is still experimental and has not been formally tested for safety or effectiveness in a randomized control trial within the United States. The FDA has allowed the use of topical Pentamidine in this research study.
Interventions
- DRUG Placebo
- DRUG Pentamidine Isethionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2020-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03403621
The ClinicalTrials.gov registry entry for NCT03403621 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03403621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03403621 about?
NCT03403621 is a clinical study titled "Hypertrophic Scar Prevention by Novel Topical Gel Application". Researchers are trying to find out more about the side effects of topical (applied to the skin) Pentamidine, to determine if it is safe for use in people. They also want to find out if topical use of Pentamidine can help treat hypertrophic scars. Pentamidine is a medicine that is currently used to ...
What is the current status of trial NCT03403621?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2018-03-05. Estimated completion is 2020-02-26.
What interventions are being tested in trial NCT03403621?
The interventions under investigation include: Placebo (DRUG), Pentamidine Isethionate (DRUG).
Who is sponsoring clinical trial NCT03403621?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.